

4. In your December 10, 2018 response to the CBER Information Request dated November 29, 2018, you responded to item 3a, which asked that you state in the SOP when the (b) (4) . You responded that "(b) (4) . Please note that we are not asking when the (b) (4) is prepared, but rather when the (b) (4)

(b) (4)

Please include this information in the SOP. If there is a time range between (b) (4), please provide data demonstrating no significant effect of this time interval on assay performance.

5. Please describe how future validity control lots will be qualified prior to use in the Virus Concentration test and specify the shelf life of the validity controls. Please include this information in section 3.2.P.6 Reference Standards or Materials and as an appendix to the SOP Q_0144050.
6. In your specificity experiment performed for the validation of the Virus Concentration assay, (b) (4)

- (b) (4)

- (b) (4)

Please establish appropriate validity criteria for your validation experiments.

7. Please state whether the Virus Concentration test submitted in the BLA is the same as the Virus Concentration test used to obtain the potencies of the batches that were used in the pivotal clinical studies. If these tests differ, please identify the differences and provide information or data that assures that the two versions of the test would yield similar titers.

The following comment refers to the Virus Identification test for release of the Finished Product:

8. Please provide the description and validation of the Virus Identification test performed for release of the Finished Product according to the (b) (4) method referenced in section 3.2.P.5.1 (page 4 of 4).

Please submit your response in an amendment to STN 125682 by January 28, 2019. In your response, please include a table stating where all provided information can be found in the BLA. We recommend that you restate each item and follow it with your explanation or

clarification. Use of this format helps to organize the relevant information and provides a self-contained document that facilitates future reference. If you have any questions, please contact Kirk Prutzman, Stephanie Polo or Ramachandra Naik at 301-796-2460.

Best regards,

Stephanie Polo

Primary Reviewer/Regulatory Project Manager

Center for Biologics Evaluation and Research
Office of Vaccines Research and Review
U.S. Food and Drug Administration
Tel: 301-796-2640
stephanie.polo@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.